A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A quantitative modeling and simulation framework to support candidate and dose selection of anti‐SARS‐CoV‐2 monoclonal antibodies to advance bamlanivimab …
E Chigutsa, E Jordie, M Riggs, A Nirula… - Clinical …, 2022 - Wiley Online Library
Neutralizing monoclonal antibodies (mAb), novel therapeutics for the treatment of
coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome …
coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome …
Tolerability, safety, pharmacokinetics, and immunogenicity of a novel SARS-CoV-2 neutralizing antibody, etesevimab, in Chinese healthy adults: a randomized …
X Wu, N Li, G Wang, W Liu, J Yu, G Cao… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly
worldwide. This study is the first to report the tolerability, safety, pharmacokinetics (PK), and …
worldwide. This study is the first to report the tolerability, safety, pharmacokinetics (PK), and …
Effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients
N Piccicacco, K Zeitler, J Montero… - Open Forum …, 2021 - academic.oup.com
Abstract Background Coronavirus disease 2019 (COVID-19) continues to stress the health
care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID …
care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID …
Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease
JY Lee, JY Lee, JH Ko, M Hyun, HA Kim… - Frontiers in …, 2021 - frontiersin.org
Objective To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent
for treating coronavirus 2019 (COVID-19). Methods A retrospective cohort study was …
for treating coronavirus 2019 (COVID-19). Methods A retrospective cohort study was …
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
BACKGROUND Clinical data to support the use of bamlanivimab for the treatment of
outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed …
outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed …
Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro
The IgG1 monoclonal antibody (mAb) bamlanivimab (LY-CoV555) prevents viral attachment
and entry into human cells by blocking attachment to the ACE2 receptor. However, whether …
and entry into human cells by blocking attachment to the ACE2 receptor. However, whether …
Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus disease 2019 (COVID-19): a real-world experience
JP Verderese, M Stepanova, B Lam… - Clinical Infectious …, 2022 - academic.oup.com
Abstract Background Neutralizing monoclonal antibody (NmAb) treatments have received
Emergency Use Authorization to treat patients with mild or moderate COVID-19 infection. To …
Emergency Use Authorization to treat patients with mild or moderate COVID-19 infection. To …
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …
antibody regimens for COVID-19. Methods This systematic review and random-effects …
Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern
M Falcone, G Tiseo, B Valoriani, C Barbieri… - Infectious diseases and …, 2021 - Springer
Introduction The aim of this study was to evaluate the risk of hospitalization or death in
patients infected by SARS-CoV2 variants of concern (VOCs) receiving combinations of …
patients infected by SARS-CoV2 variants of concern (VOCs) receiving combinations of …